Navidea Biopharmaceuticals (NAVB) Competitors $0.0005 0.00 (0.00%) As of 08/7/2025 10:25 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock NAVB vs. VINC, UPC, ORGS, SMFL, SYRS, VRPX, SCPS, EVLO, CMRA, and GNCAQShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Vincerx Pharma (VINC), Universe Pharmaceuticals (UPC), Orgenesis (ORGS), Smart for Life (SMFL), Syros Pharmaceuticals (SYRS), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), and Genocea Biosciences (GNCAQ). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Its Competitors Vincerx Pharma Universe Pharmaceuticals Orgenesis Smart for Life Syros Pharmaceuticals Virpax Pharmaceuticals Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Navidea Biopharmaceuticals (NYSE:NAVB) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment. Is NAVB or VINC more profitable? Navidea Biopharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Vincerx Pharma N/A -248.33%-132.73% Does the media prefer NAVB or VINC? In the previous week, Vincerx Pharma had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Vincerx Pharma and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Vincerx Pharma Neutral Do analysts prefer NAVB or VINC? Vincerx Pharma has a consensus target price of $40.00, suggesting a potential upside of 81,532.65%. Given Vincerx Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Vincerx Pharma is more favorable than Navidea Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, NAVB or VINC? Navidea Biopharmaceuticals has higher revenue and earnings than Vincerx Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K6.16-$15.18MN/AN/AVincerx PharmaN/AN/A-$40.16M-$20.600.00 Do institutionals and insiders hold more shares of NAVB or VINC? 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, NAVB or VINC? Navidea Biopharmaceuticals has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. SummaryNavidea Biopharmaceuticals and Vincerx Pharma tied by winning 5 of the 10 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$50K$16.73M$5.46B$20.69BDividend YieldN/AN/A3.99%3.66%P/E RatioN/AN/A30.0128.66Price / Sales6.1618.73372.2166.53Price / CashN/AN/A35.9423.59Price / BookN/A0.018.154.32Net Income-$15.18M-$15.34M$3.26B$995.66M7 Day PerformanceN/A-2.15%1.05%2.16%1 Month PerformanceN/A-8.47%2.75%-0.31%1 Year PerformanceN/A-42.17%28.06%15.06% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$50K$8.13K0.0010VINCVincerx Pharma2.6901 of 5 stars$0.04-2.5%$40.00+114,185.7%-99.6%$183KN/A0.0060News CoverageUpcoming EarningsGap DownUPCUniverse PharmaceuticalsN/A$3.65-0.7%N/A-99.8%$154K$19.29M0.00220News CoverageORGSOrgenesis1.2236 of 5 stars$0.02-80.2%N/AN/A$106K$662K0.00150Gap DownSMFLSmart for LifeN/A$0.01+161.9%N/A-99.6%$78K$11.11M0.00110Gap UpSYRSSyros Pharmaceuticals4.0463 of 5 stars$0.00flat$3.33+302,930.3%-100.0%$30K$386K0.00120Gap DownVRPXVirpax PharmaceuticalsN/A$0.01flatN/A-100.0%$14KN/A0.007Gap UpSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120News CoverageOptions VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070 Related Companies and Tools Related Companies Vincerx Pharma Competitors Universe Pharmaceuticals Competitors Orgenesis Competitors Smart for Life Competitors Syros Pharmaceuticals Competitors Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NAVB) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAVB Stock Alerts